Skip to main content
Search

# Ovarian cancer

3 related articles

Subscribe to updates
  1. medRxiv

    Ovarian mass triage without a fixed biomarker panel: adaptive plasma proteomics reaches a summary AUC of 0.835 across five validation cohorts

    Pre-operative triage of adnexal masses has relied on CA-125, HE4 and ultrasound O-RADS, all with limited sensitivity and specificity. ADAPT-MS instead retrains a classifier for each sample on the proteins actually measured, reading discovery-mode plasma mass spectrometry data directly. Across 623 samples in five independent validation cohorts the classifier reached a summary AUC of 0.835, comparable to O-RADS alone, and rose to 0.922 when combined with O-RADS.

  2. Epigenetic Mechanisms and Clinical Translation in Ovarian Cancer: From Molecular Pathways to Precision Therapy

    This review systematically examines how DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA networks drive chemoresistance and recurrence in ovarian cancer, summarizes clinical trial results of epigenetic agents (DNMT, HDAC, and EZH2 inhibitors) combined with PARP inhibitors or immunotherapy, and reviews biomarker advances based on circulating cfDNA methylation, circulating miRNAs, and AI-based liquid biopsy platforms, proposing a precision oncology framework for patient stratification and real-time monitoring of chemoresistance.

  3. Cancer

    The Evolving Role of Immunotherapy in Ovarian Cancer: From Empirical Use Toward Biology-Driven Combination and Precision Strategies

    This review synthesizes the clinical evidence and resistance mechanisms for immunotherapy in ovarian cancer, noting that single-agent immune checkpoint inhibitors achieve objective response rates generally below 15% in recurrent disease, that the clearest added benefit appears in chemotherapy-based combinations for PD-L1-positive platinum-resistant disease (e.g., in ENGOT-ov65/KEYNOTE-B96, median overall survival 18.2 vs 14.0 months in the CPS >=1 population, HR 0.

You’re all caught up